34th Piper Sandler Annual Healthcare Conference and RBC Capital Markets Healthcare Private Company Virtual Conference

Press Releases
Written By Thryv Therapeutics

MONTREAL, Quebec, Canada | November 17, 2022

Thryv Therapeutics Inc., a biopharmaceutical company focused on a precision medicine approach to treat Long QT Syndromes via SGK1 inhibition and resistant cancers, will participate in a fireside chat and host investor meetings at the upcoming 34th Piper Sandler Annual Healthcare Conference, and will participate in a fireside chat at the upcoming 2022 RBC Capital Markets Healthcare Private Company Conference.

Mr. Paul F. Truex will provide a full update on Thryv’s progress to date with the development of a number of highly potent SGK1 inhibitors for all major forms of Long QT Syndrome, atrial fibrillation and resistant cancers.


Piper Sandler 34th Annual Healthcare Conference

Location: New York, NY

Fireside Chat: Tuesday, November 29th, 2022 at 11:10 a.m. ET

1x1 Meetings: Tuesday, November 29th, 2022

 

RBC Capital Markets Healthcare Private Company Virtual Conference

Virtual Fireside Chat: Wednesday, December 14th, 2022

 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned pharmaceutical company pioneering a precision medicine approach through the inhibition of Serum and Glucocorticoid induced Kinase (SGK1) to treat Long QT Syndrome, Atrial Fibrillation, and resistant and rare cancers. For more information, visit www.thryvtrx.com

Media Inquiries

daphne@thryvtrx.com | 514 973 0915

Thryv Therapeutics
Previous

Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., Appointed to Thryv’s Board of Directors
Next

Scientific Data for Thryv’s Novel SGK1 inhibitors Presented at American Heart Association and San Antonio Breast Cancer Symposium